High-dose chemotherapy (HDC) followed by autologous peripheral blood stem cell transplantation (HDC-auto-PBSCT) offers a cure for patients with lymphoma without the risk of GVHD. Conditioning regimens for Auto-SCT administered to patients in major studies have included BCNU in the BEAM or BEAC (BCNU, etoposide, cytarabine and cyclophosphamide) regimens.
2 from days − 7 to − 4, etoposide 500 mg/m 2 from days − 6 to − 4 and cyclophosphamide 60 mg/kg on days − 3 and − 2, as arranged of which was described previously, 2, 3 between August 1999 and December 2012 at Showa University Hospital, were enrolled. Responses to first-line chemotherapy, prior to chemotherapy of HDC-auto-PBSCT, and HDC-auto-PBSCT themselves were judged according to the International Working Group response criteria without evaluation using positron emission tomographycomputed tomography findings. 6 The responses to prior chemotherapies of HDC-auto-PBSCT were defined as disease status at SCT (CR as CR or CR/unconfirmed [CRu] ; non-CR as less than CRu) and chemosensitivity at SCT (chemosensitive as CR, CRu or PR; chemoresistant as less than PR). Pre-transplantation factors, the prognostic impacts of most of which have been reported previously, were evaluated using univariate and multivariate analyses. The factors included laboratory parameters before HDC-auto-PBSCT, which were defined as the values determined between the latest chemotherapy end date and the administration of MCEC conditioning. All P values were determined from 2-tailed tests, with P o 0.05 considered significant. All statistical analyses were performed using EZR version 1.24 (Kanda Y, Saitama Medical Center, Jichi Medical University, Saitama, Japan). The study protocol was approved by the Ethics Committee of Showa University (Tokyo, Japan), which adhered to the principles of the Declaration of Helsinki.
Thirty-eight patients (25 males and 13 females) with non-Hodgkin lymphoma who received the MCEC regimen because of non-CR achievement by first-line chemotherapy or because of relapse before SCT were enrolled. These patients included 14 patients who were administered rituximab at a dose of 375 mg/m 2 around initiation of the MCEC-based regimen (5 patients received rituximab on day − 9, 1 on day − 1, 7 on day 1, 1 on day 6). The last day of follow-up was in March 2014. The median age of patients at the time of transplantation was 56 (range, 19-69) years. Histological types in these patients included 26 diffuse large B-cell lymphomas, 6 follicular lymphomas, 2 mantle-cell lymphomas and 4 peripheral T-cell lymphomas. The median time from the diagnosis to PBSCT was 16 (range, 6-246) months, and the median number of prior chemotherapy regimens before MCEC (excluding PBSCharvesting regimens) was 2 (range, 1-6). According to chemosensitivities at SCT, 28 patients were chemosensitive (15 CR/CRu; 13 PR) and 10 were chemoresistant. Salvage SCTs were performed because of chemorefractory disease at first-line therapy (n = 11), relapse (n = 24) or both (n = 3). Of the 34 patients with B-cell lymphoma, 32 were administered rituximab before HDC-auto-PBSCT.
The median numbers of nucleated cells and CD34 + cells transfused were 4.07 × 10 8 /kg (range, 0.84-10.7 × 10 8 /kg) and 5.70 × 10 6 /kg (range, 1.01-36.5 × 10 6 /kg), respectively. Neutrophil engraftment occurred in all patients, except the one who died on day 1 of SCT. The median day of myeloid engraftment (the first of 3 consecutive days with an ANC ⩾ 500/μL) was day 9 (range, days 7-15). All patients were administered G-CSF from day 1. The median duration of G-CSF administration was 12 days (range, 2-38 days).
With regard to the outcome of HDC-auto-PBSCT, the 5-year OS and PFS after the transplantations were 50.8 and 37.3%, respectively (Figures 1a and b) . Of the 23 patients with non-CR state at HDC-auto-PBSCT, 15 patients (65%) achieved CR after HDC-auto-PBSCT. Three patients had non-relapse mortality-one patient died of unknown causes at day 30 and two died from secondary malignancies.
Univariate analyses with the log-rank test identified unfavorable factors for OS and PFS: non-CR state at HDC-auto-PBSCT, chemoresistant state at SCT, ⩾ 3 regimens before HDC-auto-PBSCT, C-reactive protein (CRP) levels 41.0 mg/dL both at diagnosis of lymphoma and before HDC-auto-PBSCT, and soluble IL-2 receptor (sIL-2R) levels 4520 U/mL (upper limit of normal) before HDC-auto-PBSCT. Multivariate analyses using the Cox regression analysis including these factors revealed that CRP levels at diagnosis and sIL-2R levels before HDC-auto-PBSCT remained significant for OS and PFS, irrespective of chemosensitivity at SCT (Table 1) .
To propose a novel prognostic model of survival following auto-PBSCT, we defined the following scoring system (scores 0-3) according to the following three items (with scores in parentheses): chemosensitivity at SCT (0 as chemosensitive, 1 as chemoresistant), CRP levels at diagnosis of lymphoma Abbreviations: CI, confidence interval; CRP, C-reactive protein; HR, hazard ratio; IPI, the International Prognostic Index; sIL-2R, soluble IL-2 receptor.
a Peripheral T-cell lymphomas (PTCLs) included 2 PTCLs, not otherwise specified, 1 angioimmunoblastic T-cell lymphoma, and 1 anaplastic large cell lymphoma, ALKnegative.
b Failure-free survival (FFS) time was defined as the time from disease diagnosis until relapse or initiation of second line therapy.
c
The values were measured between days − 37 and − 8 of SCTs. Letter to the Editor sIL-2R level 4520 U/mL). Among the 36 patients for whom sufficient data were available, the score stratified the 1-year OS into 79.5, 70.0, and 40.0% and the 1-year PFS into 61.4, 44.4, and 20.0% as scores 1 (n = 11), 2 (n = 20) and 3 (n = 5), respectively (Figures 1c and d) .
Our prognostic model revealed that the prognostic impact of elevated CRP levels at diagnosis remained significant even after the introduction of HDC-auto-PBSCT. CRP is considered a marker of IL-6 bioactivity and had been shown to have the same value as IL-6 as an adverse prognostic marker of non-Hodgkin lymphoma. [7] [8] [9] Studies have shown that IL-6 produced by nontumor cells could exert growth-stimulatory effects on lymphoma cells and could attenuate the effects of chemoradiation therapy in a myeloma model. 10, 11 Available evidence has shown that IL-6 is among the inflammatory cytokines encoded by target genes of NF-κB-activated signaling pathways, 12 which is an important molecular characteristic of aggressive diffuse large B-cell lymphomas. Thus, increased CRP levels may represent the development and progression of lymphomas with chemorefractory phenotypes.
The impact of sIL-2R levels before HDC with Auto-SCT, rather than at diagnosis, has not been studied previously. 13, 14 However, increased sIL-2R levels before HDC with Auto-SCT may possibly indicate the status of residual disease, which is clinically important but not evaluated by conventional contrastenhanced CT. Similarly, a recent study reported the prognostic impact of pre-transplant residual disease according to positron emission tomography-computed tomography findings on survival after HDC with Auto-SCT. 15 Alternatively, the sIL-2R levels before HDC with Auto-SCT may indicate dysregulated immune responses in a host with residual non-Hodgkin lymphoma, which may hamper the therapeutic effects of MCEC regimen as salvage chemotherapy.
Our prognostic model, which included CRP and sIL-2R levels as parameters, indicated that a majority of patients with chemorefractory lymphoma would die because of progressive disease after Auto-SCT. The outcome of our study, which was nearly identical to that reported with both the MCEC 4,5 and BCNU-based regimens, 1 remains unsatisfactory for these regimens to be used as salvage therapies. Our findings indicate that both CRP and sIL-2R levels may serve as useful markers for the selection of appropriate therapeutic strategies before transplantation in high-risk lymphoma patients.
